The Board of Directors of Natural Capsules Limited, in their meeting held on May 27, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026 [cite: 1]. The standalone financial results highlight a significant performance, with revenue from operations for the quarter ended March 31, 2026, reaching 5,080.14 Lakhs, compared to 3,414.64 Lakhs in the previous quarter (December 31, 2025) and 4,436.07 Lakhs in the corresponding quarter of the previous year (March 31, 2025) [cite: 1]. The net profit after tax for the current quarter stood at 551.81 Lakhs, showing a substantial recovery from 36.23 Lakhs in the preceding quarter and an increase from 262.66 Lakhs in the corresponding quarter last year [cite: 1].

Natural Capsules Limited is a prominent Indian manufacturer specializing in the production of hard gelatin capsules and other pharmaceutical delivery systems [cite: 1]. The company has expanded its operations, establishing a presence in the Active Pharmaceutical Ingredients (API) segment, with its subsidiary, Natural Biogenex Private Limited, having commenced commercial operations on March 31, 2025 [cite: 1]. Recent corporate updates include the re-appointment of Mr. Laxminarayana Moondra as Whole-time Director for a three-year term and the appointment of Mr. Akshay Dutta as the Company Secretary and Compliance Officer, effective May 27, 2026 [cite: 1]. Additionally, the company allotted 25,000 equity shares under the Employee Stock Option Plan (ESOP) 2025 [cite: 1].

For the financial year ended March 31, 2026, the company reported a standalone net profit of 1,121.39 Lakhs compared to 671.11 Lakhs in the previous fiscal year [cite: 1]. The diluted earnings per share (EPS) for the year reached 10.79 [cite: 1]. The company’s financial results reflect the impact of operational challenges earlier in the year, including a temporary shutdown of a manufacturing unit due to regulatory issues from December 26, 2025, which resumed operations on January 30, 2026 [cite: 1]. The consolidated financial statements indicate that while the capsule segment remains a core contributor, the API segment is in a phase of scaling up, which has influenced overall profitability metrics [cite: 1].